BPMC
Connor, Clark & Lunn Investment Management (CC&L)’s Blueprint Medicines BPMC Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-183,947
| Closed | -$16.3M | – | 1518 |
|
|
2025
Q1 | $16.3M | Buy |
183,947
+41,230
| +29% | +$3.65M | 0.07% | 228 |
|
|
2024
Q4 | $12.4M | Buy |
142,717
+137,585
| +2,681% | +$12M | 0.06% | 270 |
|
|
2024
Q3 | $475K | Buy |
+5,132
| New | +$475K | ﹤0.01% | 1110 |
|
|
2024
Q1 | – | Sell |
-6,472
| Closed | -$597K | – | 1532 |
|
|
2023
Q4 | $597K | Buy |
+6,472
| New | +$597K | ﹤0.01% | 995 |
|
|
2023
Q3 | – | Sell |
-12,994
| Closed | -$821K | – | 1374 |
|
|
2023
Q2 | $821K | Sell |
12,994
-10,724
| -45% | -$678K | ﹤0.01% | 858 |
|
|
2023
Q1 | $1.07M | Buy |
23,718
+9,265
| +64% | +$417K | 0.01% | 693 |
|
|
2022
Q4 | $633K | Buy |
14,453
+10,855
| +302% | +$476K | ﹤0.01% | 814 |
|
|
2022
Q3 | $237K | Buy |
+3,598
| New | +$237K | ﹤0.01% | 962 |
|
|
2021
Q1 | – | Sell |
-9,525
| Closed | -$1.07M | – | 990 |
|
|
2020
Q4 | $1.07M | Buy |
+9,525
| New | +$1.07M | 0.01% | 621 |
|